{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:01:44Z","timestamp":1758042104049,"version":"3.44.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ajo.2016.06.040","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T12:02:58Z","timestamp":1469966578000},"page":"xiv-xvi","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad"],"prefix":"10.1016","volume":"169","author":[{"given":"Daniel E.","family":"Croft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Michels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan F.","family":"Cruess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2016.06.040_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1167\/iovs.09-3813","article-title":"The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model","volume":"51","author":"Holz","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2016.06.040_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00347-014-3217-7","article-title":"Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany","volume":"112","author":"Ziemssen","year":"2015","journal-title":"Ophthalmologe"},{"author":"European Medicines Agency","key":"10.1016\/j.ajo.2016.06.040_bib3"},{"issue":"12","key":"10.1016\/j.ajo.2016.06.040_bib4","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2016.06.040_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2016.05.016","article-title":"Visual acuity of eyes with early persistent retinal fluid from neovascular age-related macular degeneration in the VIEW studies","author":"Jaffe","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2016.06.040_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2016.04.020","article-title":"Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study","author":"Hoerauf","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2016.06.040_bib8","first-page":"22","article-title":"Drug research and price controls","volume":"23","author":"Vernon","year":"2003","journal-title":"Regulation"},{"key":"10.1016\/j.ajo.2016.06.040_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00717-012-0072-2","article-title":"The intravitreal injection: variations in regulations, cost and reimbursement in Europe","volume":"26","author":"Michels","year":"2012","journal-title":"Spekt Augenheilkd"},{"issue":"6","key":"10.1016\/j.ajo.2016.06.040_bib12","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR Study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939416303142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939416303142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:33:01Z","timestamp":1757597581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939416303142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":9,"alternative-id":["S0002939416303142"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2016.06.040","relation":{},"ISSN":["0002-9394"],"issn-type":[{"type":"print","value":"0002-9394"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2016.06.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2016.04.020","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}